Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma
Neuro-Oncology Advances · 06.01.2025 · 7 (1)
DOI: 10.1093/noajnl/vdaf030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 07.02.2025. Verfasst von Nikita Das und 5 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Background
Over the past decade, novel immune checkpoint inhibitors have revolutionized melanoma treatment. These new therapies are associated with complex immune-related adverse events. This study examines whether combination anti-PD-1/CTLA-4 immunotherapy for melanoma is associated with increased incidence of neurologic irAEs (n-irAEs) compared to anti-PD-1 monotherapy.
Methods
A retrospective, multicenter study using TriNetX identified adult melanoma patients receiving anti-PD-1 monotherapy (pembrolizumab or nivolumab) (Cohort 1: n = 10,586) and patients receiving anti-PD-1/CTLA-4 combination therapy (nivolumab + ipilimumab) (Cohort 2: n = 5,705). Propensity score matching generated final cohorts (n = 5,185) using covariates: gender, race, age at diagnosis, TNM staging, nervous system metastasis, and history of neurologic disease. Odds ratios (OR) for n-irAE subtypes at 3- and 5-year post-therapy initiation were calculated, and Kaplan–Meier analyses assessed overall survival by aggregate n-irAE status in each cohort.
Results
At 3 years, patients receiving combination immunotherapy exhibited increased risk of immune-related meningitis (OR: 2.6, 95% CI: [1.7, 4.1]) and encephalitis (OR: 3.0, 95% CI: [1.9, 4.9]), peripheral neuropathy (OR: 1.3, 95% CI [1.1, 1.5]), and myopathy (OR: 1.5, 95% CI: [1.1, 2.1]), but no significantly increased risk of demyelinating syndromes (OR: 1.5, 95% CI: [0.82, 2.6]), vasculitis (OR: 0.88, 95% CI: [0.43, 1.8]), or neuromuscular junction disorders (OR: 1.3, 95% CI: [0.87, 2.0]). At 5 years, these trends for risk of neurologic irAEs persisted. There was no significant difference in overall survival by n-irAE presence at 3 or 5 years in either cohort.
Conclusions
Melanoma patients receiving combination anti-PD-1/CTLA-4 immunotherapy have greater long-term risk of n-irAEs than patients receiving anti-PD-1 monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, _Case Western Reserve University, Cleveland, Ohio, USA.
- Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, USA.
- Department of Neurological Surgery, The MetroHealth System, Cleveland, Ohio, USA.
- Department of Hematology/Oncology, The MetroHealth System, Cleveland, Ohio, USA.
ORCID-Profile: Nikita Das, Deven Reddy
Förderung
- National Institutes of Health
Zitieren
APA
Das, N., Dhamija, R., Kaelber, D. C., Kelly, M., Xie, P., & Reddy, D. (2025). Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdaf030
Vancouver
Das N, Dhamija R, Kaelber DC, Kelly M, Xie P, Reddy D. Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma. Neuro-Oncology Advances. 2025;7(1). doi:10.1093/noajnl/vdaf030
BibTeX
@article{Das2025,
author = {Das, Nikita and Dhamija, Ravi and Kaelber, David C and Kelly, Michael and Xie, Peter and Reddy, Deven},
title = {Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma},
journal = {Neuro-Oncology Advances},
year = {2025},
volume = {7},
number = {1},
doi = {10.1093/noajnl/vdaf030}
}
EUVIMED